Steatotic Liver Disease: Mortality Risks

by | Jun 19, 2025 | Uncategorized | 0 comments


From JAMA Internal Medicine, June 16, 2025: Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease.



Objective:
To compare the risk of adverse liver outcomes, major cardiovascular events, and all-cause mortality among people with different levels of liver fibrosis and hepatitis.

🔍 The Study Design

  • Cohort: Adults tested for hepatitis B or C, followed via national health data.
  • Groups: Stratified by liver disease severity:
    • Minimal fibrosis
    • Moderate fibrosis
    • Cirrhosis
    • Resolved infection
  • Outcomes measured:
    • Progression to liver-related complications (e.g., decompensation, liver cancer)
    • Major adverse cardiovascular events (MACE: heart attack, stroke)
    • All-cause mortality

📈 The Key Findings

  1. Liver Complications:
    • Risk increased sharply with disease severity:
      • Cirrhosis → >20× higher rate of liver complications vs minimal fibrosis
      • Moderate fibrosis → ~5× higher risk
  2. Cardiovascular Events:
    • Elevated risks persisted after adjusting for age, sex, and other cardiovascular risk factors.
    • Individuals with cirrhosis had a significantly higher risk of MACE than those with minimal fibrosis.
  3. All-Cause Mortality:
    • Mortality rose progressively with liver disease severity.
    • Even those with resolved infection (post-SVR or HBV suppression) had higher mortality than uninfected controls.

🧠 The Interpretation & Implications

  • Multisystem risk: Advanced liver fibrosis doesn’t only threaten liver health—it increases cardiovascular risk and death.
  • Monitoring importance: Even after viral cure or suppression, long-term surveillance is critical, especially for cardiovascular health.
  • Holistic care: Management should include:
    • Ongoing liver monitoring
    • Cardiovascular risk factor control (e.g., blood pressure, cholesterol)
    • Patient education on overall health and lifestyle

✅ The Bottom Line

Patients with moderate to severe liver fibrosis—regardless of current infection status—face significantly higher risks of liver events, heart attacks or strokes, and death. Healthcare providers should implement integrated care strategies that go beyond viral eradication to include ongoing monitoring and cardiovascular risk reduction.f

a